Physician profile
Tracy Turner
NPI 1194449009
$3,432.47
in general payments reported to CMS, 2019-2025
21 companies · $2,081 in 2025
The $2,081 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.61 · 2022: $18.19 · 2023: $457 · 2024: $862 · 2025: $2,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,101 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,100.69 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $743.45 | 2023-2025 | Tremfya |
| Abbvie INC. | $648.65 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $365.42 | 2023-2025 | Absorica Ld, Winlevi |
| Amgen INC. | $262.24 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $176.93 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $176.03 | 2024-2025 | Sotyktu |
| Ucb, INC. | $168.66 | 2025 | Bimzelx |
| Lilly USA, LLC | $133.75 | 2022-2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $125.81 | 2025 | Nemluvio |
| Incyte Corporation | $124.51 | 2024-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $108.58 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $80.93 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $56.28 | 2024-2025 | Dupixent |
| Dermavant Sciences, INC. | $45.13 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.51 | 2025 | Jublia, Cabtreo, Siliq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $40.57 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $38.38 | 2024-2025 | Ycanth |
| Mayne Pharma Commercial LLC | $33.46 | 2023 | |
| Journey Medical Corporation | $24.98 | 2025 | |
| Organon LLC | $22.59 | 2025 | Vtama |
| Novo Nordisk INC | $14.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.